Iantrek

Executive Summary

Iantrek is a privately held medical device company based in San Diego, focused on micro-interventional ophthalmic surgery for glaucoma. Its lead product, AlloFlo™ Uveo, is a bio-interventional therapy designed to enhance total outflow through the uveoscleral pathway, addressing a key unmet need in glaucoma management. The company's technology aims to improve surgical outcomes and reduce the burden of intraocular pressure control. With its initial product already commercialized, Iantrek is positioned to capture market share in the growing glaucoma device space. However, as a private company with limited public data on revenue or clinical studies, its long-term trajectory hinges on adoption rates and potential competitive responses from established players. The company's innovation in targeting the uveoscleral pathway differentiates it from traditional trabecular meshwork-focused devices.

Upcoming Catalysts (preview)

• Q3 2026AlloFlo Uveo sales ramp and key opinion leader uptake70% success
• Q1 2027Publication of clinical outcomes in peer-reviewed journal50% success
• Q2 2027Partnership or distribution agreement with major ophthalmic company30% success